Loading...

Kiniksa Pharmaceuticals

Nasdaq:KNSA
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KNSA
Nasdaq
$729M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
  • Kiniksa Pharmaceuticals has significant price volatility in the past 3 months.
KNSA Share Price and Events
7 Day Returns
-3%
NasdaqGS:KNSA
-1%
US Biotechs
-1.2%
US Market
1 Year Returns
-14.1%
NasdaqGS:KNSA
-11.9%
US Biotechs
3.3%
US Market
KNSA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kiniksa Pharmaceuticals (KNSA) -3% -3.8% -12.8% -14.1% - -
US Biotechs -1% -3.6% -0.7% -11.9% 5.4% 7.4%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • KNSA underperformed the Biotechs industry which returned -11.9% over the past year.
  • KNSA underperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Kiniksa Pharmaceuticals's competitors could be found in our database.

Value

 Is Kiniksa Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kiniksa Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $13.33.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kiniksa Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kiniksa Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:KNSA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-3.66
NasdaqGS:KNSA Share Price ** NasdaqGS (2019-07-22) in USD $13.33
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.44x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kiniksa Pharmaceuticals.

NasdaqGS:KNSA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:KNSA Share Price ÷ EPS (both in USD)

= 13.33 ÷ -3.66

-3.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kiniksa Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Kiniksa Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Kiniksa Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:KNSA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
48.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.79x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kiniksa Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kiniksa Pharmaceuticals's assets?
Raw Data
NasdaqGS:KNSA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $5.60
NasdaqGS:KNSA Share Price * NasdaqGS (2019-07-22) in USD $13.33
United States of America Biotechs Industry PB Ratio Median Figure of 437 Publicly-Listed Biotechs Companies 2.93x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqGS:KNSA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:KNSA Share Price ÷ Book Value per Share (both in USD)

= 13.33 ÷ 5.60

2.38x

* Primary Listing of Kiniksa Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kiniksa Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Kiniksa Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kiniksa Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kiniksa Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kiniksa Pharmaceuticals expected to grow at an attractive rate?
  • Kiniksa Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Kiniksa Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Kiniksa Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:KNSA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:KNSA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 48.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:KNSA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:KNSA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 928 361 1
2022-12-31 503 83 1
2021-12-31 61 0 -196 3
2020-12-31 0 0 -218 4
2019-12-31 0 0 -187 4
NasdaqGS:KNSA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -129 -153
2018-12-31 -81 -103
2018-09-30 -77 -93
2018-06-30 -67 -85
2018-03-31 -60 -76
2017-12-31 -50 -65
2016-12-31 -22 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kiniksa Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Kiniksa Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:KNSA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Kiniksa Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:KNSA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.71 5.71 5.71 1.00
2022-12-31 1.31 1.31 1.31 1.00
2021-12-31 -2.91 -2.49 -3.34 2.00
2020-12-31 -3.78 -3.72 -3.85 3.00
2019-12-31 -3.65 -3.52 -3.83 3.00
NasdaqGS:KNSA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -3.66
2018-12-31 -3.49
2018-09-30 -5.20
2018-06-30 -12.30
2018-03-31 -36.53
2017-12-31 -35.85
2016-12-31 -91.61

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kiniksa Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Kiniksa Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kiniksa Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kiniksa Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kiniksa Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kiniksa Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Kiniksa Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kiniksa Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kiniksa Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kiniksa Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:KNSA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -153.07 27.61 131.86
2018-12-31 -103.23 22.50 85.66
2018-09-30 -93.35 17.15 79.59
2018-06-30 -84.97 13.67 73.16
2018-03-31 -75.91 11.25 65.44
2017-12-31 -64.87 9.45 55.96
2016-12-31 -23.97 6.85 17.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kiniksa Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kiniksa Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kiniksa Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kiniksa Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kiniksa Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kiniksa Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kiniksa Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kiniksa Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kiniksa Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kiniksa Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7.5425385839276E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kiniksa Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGS:KNSA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 306.52 0.00 326.53
2018-12-31 279.27 0.00 307.30
2018-09-30 318.91 0.00 337.86
2018-06-30 341.80 0.00 359.19
2018-03-31 205.48 0.00 221.11
2017-12-31 30.06 0.00 45.56
2016-12-31 54.17 0.00 55.97
  • Kiniksa Pharmaceuticals's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Kiniksa Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kiniksa Pharmaceuticals has sufficient cash runway for 2.4 years based on current free cash flow.
  • Kiniksa Pharmaceuticals has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 60.8% each year.
X
Financial health checks
We assess Kiniksa Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kiniksa Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kiniksa Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kiniksa Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Kiniksa Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kiniksa Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kiniksa Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:KNSA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:KNSA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kiniksa Pharmaceuticals has not reported any payouts.
  • Unable to verify if Kiniksa Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kiniksa Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kiniksa Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Kiniksa Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Kiniksa Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kiniksa Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kiniksa Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kiniksa Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sanj Patel
COMPENSATION $7,308,557
AGE 49
TENURE AS CEO 4 years
CEO Bio

Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals since July 2015. Before founding Kiniksa Pharmaceuticals in 2015, Mr. Patel founded Synageva BioPharma Corp. in June 2008 and served as its President and Chief Executive Officer since June 2008 until June 2015 and also served as its Secretary. He took Synageva public in November 2011, raising more than $1 billion in capital in less than five years and he led the $9.5 billion (including cash) acquisition of Synageva by Alexion Pharmaceuticals in June 2015. He joined Synageva from Genzyme Corporation, where he served as the Head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics and led the commercial U.S. launch for Myozyme®. He was employed at Genzyme Corporation from 1999 to June 2008, where he held several cross-functional senior leadership roles at Genzyme including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization for several treatments. Mr. Patel led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, he held roles in clinical research and commercial development with increasing levels of responsibility at Burroughs Wellcome, Hoescht Marrion Roussel and Fujisawa Pharmaceuticals. He has 18 years of experience in the pharmaceutical and biotech industries. He has been the Chairman of Kiniksa Pharmaceuticals since July 2015. He was a Director of BioCryst Pharmaceuticals, Inc., from September 29, 2015 until June 20, 2018 and serves as Director of Syros Pharmaceuticals, Inc. since May 2016. Mr. Patel served as a Director at Intercept Pharmaceuticals, Inc. since February 18, 2014 until November 24, 2015. He served as a Director of Synageva BioPharma Corp. from June 2008 to June 22, 2015. Mr. Patel earned his B.Sc. degree with Honors in Pure and Applied Biotechnology from South Bank University, London. He attained his post-graduate management and business degree from Ealing College, London. He completed his Doctorate program in Clinical Pharmacology from King's College and The Wellcome Foundation.

CEO Compensation
  • Sanj's compensation has increased whilst company is loss making.
  • Sanj's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Kiniksa Pharmaceuticals management team in years:

4
Average Tenure
49
Average Age
  • The tenure for the Kiniksa Pharmaceuticals management team is about average.
Management Team

Sanj Patel

TITLE
CEO & Chairman of the Board
COMPENSATION
$7M
AGE
49
TENURE
4 yrs

Steve Mahoney

TITLE
President & COO
COMPENSATION
$3M
AGE
48
TENURE
2.1 yrs

John Paolini

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$3M
AGE
54
TENURE
2.9 yrs

Chris Heberlig

TITLE
Executive VP
AGE
44
TENURE
4 yrs

Mark Ragosa

TITLE
Vice President of Investor Relations

Tom Beetham

TITLE
Executive VP
AGE
49
TENURE
4 yrs

Melissa Manno

TITLE
Vice President of of Human Resources

Rasmus Holm-Jorgensen

TITLE
Senior VP

Carsten Boess

TITLE
Executive Vice President of Corporate Affairs
AGE
52

Christine Maurer

TITLE
Senior Vice President of Program Management
Board of Directors Tenure

Average tenure and age of the Kiniksa Pharmaceuticals board of directors in years:

3.2
Average Tenure
50.5
Average Age
  • The tenure for the Kiniksa Pharmaceuticals board of directors is about average.
Board of Directors

Thomas Malley

TITLE
Independent Director
COMPENSATION
$170K
AGE
50
TENURE
2.6 yrs

Sanj Patel

TITLE
CEO & Chairman of the Board
COMPENSATION
$7M
AGE
49
TENURE
4 yrs

Stephen Biggar

TITLE
Independent Director
COMPENSATION
$242K
AGE
48
TENURE
3.8 yrs

Felix Baker

TITLE
Lead Director
COMPENSATION
$258K
AGE
50
TENURE
3.8 yrs

Robert Desnick

TITLE
Chairman of Scientific Advisory Board

Kim Popovits

TITLE
Independent Director
COMPENSATION
$345K
AGE
60
TENURE
1.4 yrs

Tracey Mccain

TITLE
Independent Director
COMPENSATION
$347K
AGE
51
TENURE
1.4 yrs

Barry Quart

TITLE
Independent Director
COMPENSATION
$166K
AGE
62
TENURE
3.8 yrs

Rich Levy

TITLE
Independent Director
AGE
61
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Kiniksa Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kiniksa Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Volatility 101: Should Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Have Dropped 23%?

View our latest analysis for Kiniksa Pharmaceuticals Kiniksa Pharmaceuticals hasn't yet reported any revenue yet, so it's as much a business idea as an actual business. … A Different Perspective Given that the market gained 2.7% in the last year, Kiniksa Pharmaceuticals shareholders might be miffed that they lost 23%. … With the stock down 19% over the last three months, the market doesn't seem to believe that the company has solved all its problems.

Simply Wall St -

Who Really Owns Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)?

In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices. … View out our latest analysis for Kiniksa Pharmaceuticals

Simply Wall St -

Who Are The Major Shareholders Of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)?

See our latest analysis for Kiniksa Pharmaceuticals NasdaqGS:KNSA Ownership_summary Jun 1st 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.

Simply Wall St -

Company Info

Description

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company’s preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Details
Name: Kiniksa Pharmaceuticals, Ltd.
KNSA
Exchange: NasdaqGS
Founded: 2015
$729,209,132
54,704,361
Website: http://www.kiniksa.com
Address: Kiniksa Pharmaceuticals, Ltd.
Clarendon House,
2 Church Street,
Hamilton,
HM 11,
Bermuda
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS KNSA Class A Common Shares Nasdaq Global Select US USD 24. May 2018
Number of employees
Current staff
Staff numbers
111
Kiniksa Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/23 01:16
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/06/24
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.